Developing cancer therapies with the potential to prolong and improve the lives of cancer patients

We’re pursuing potential breakthroughs to make a difference in the lives of cancer patients by improving survival and reducing chemotherapy induced peripheral neuropathy.

See How

Modulating sphingolipid metabolism to potentially treat cancer and associated neuropathic pain

Our unique biologic is designed to modulate sphingolipid metabolism to target metastatic colorectal cancer while simultaneously addressing the neuropathic pain current treatments often cause

Well-tolerated biologic

BXQ-350 is a novel biologic that is an analog of a human protein and activates sphingolipids for a targeted, low-toxicity cancer treatment with an established safety profile

Unique mechanism for potential cancer treatment

By decreasing cancer-proliferating Sphingosine-1-Phosphate (S1P), and increasing anti-cancer ceramide, BXQ-350 is designed to create an anti-tumor environment where cancer cells enter programmed cell death

Neuroprotective properties

By modulating sphingolipids that play a critical role in both cancer and pain, clinical data suggest BXQ-350 could prevent or even reverse chemotherapy-induced peripheral neuropathy (CIPN)

Addressing an unmet need

Colorectal cancer, the second leading cause of death among cancers, is associated with late-stage diagnosis, poor outcomes, and challenging side effects from current treatment options. BXQ-350 has the potential to redefine metastatic colorectal cancer (mCRC) treatment with encouraging Phase 1b/2a data in first line mCRC.

Learn More

4th _{most common}

CRC (Colorectal Cancer) is the 4th most common cancer in the U.S. and the 3rd most common globally

153k

new CRC diagnoses and approx. 50,000 deaths in the U.S. each year*

15%

5 year Overall Survival for metastatic CRC

4 in 10

Chemotherapy Linked to Chronic Painful Neuropathy for 4 in Every 10 Patients

*SOURCES: Colorectal Cancer — Cancer Stat Facts and Colorectal Cancer Statistics | How Common Is Colorectal Cancer? | American Cancer Society

“BXQ-350’s mechanism of action lends itself to potential benefit in metastatic colorectal patients and peripheral neuropathy. Severe neuropathy is a major reason that patients need dose reductions or discontinuation of chemotherapy for colorectal cancer, and BXQ-350 has been shown to possess potential anti-neuropathy properties. I am excited by the potential of BXQ-350 to reduce or even potentially reverse neuropathic pain in these patients.”

Dr. Reema A. Patel, MD

Associate Professor of Medicine at the Markey Cancer Center of the University of Kentucky

Where new also means different

Bexion Pharmaceuticals, a clinical-stage biopharmaceutical company, is advancing a new class of biologic therapy aimed at treating solid tumors and chemotherapy-induced peripheral neuropathy (CIPN), with the potential to expand its portfolio into additional cancer types and broader neuropathic pain treatments. Bexion has generated promising Phase 1 data across various solid tumor types, including colorectal cancer. The Company has completed enrollment in the open-label portion of its Phase 1b/2 trial, which evaluates BXQ-350 in combination with the standard of care for newly diagnosed patients with metastatic colorectal cancer (mCRC). Additionally, Bexion has completed proof-of-concept study for treating CIPN.

Bexion Pharmaceuticals is committed to innovating and developing unique patient-centered therapeutics. With a multidisciplinary team of experts, Bexion is advancing a pipeline directed at treating solid tumors and chemotherapy-induced peripheral neuropathy (CIPN).

Learn More

Resources

Find case studies, abstracts, and more about the breakthroughs we’re pursuing

View All